To the Editor.—
Facial flushing is a relatively uncommon reaction associated with doxorubicin administration and is more likely to occur when the drug is injected rapidly.1 The proposed mechanism in animals is doxorubicin-mediated histamine release from both basophils and mast cells.2,3Nine reports of doxorubicin-associated facial flushing in women have been received by Adria Laboratories, Columbus, Ohio. The range of age of the patients is 32 to 66 years (mean, 52.7 years). The patients received doxorubicin for non-Hodgkin's lymphoma, Hodgkin's disease, leiomyosarcoma, or carcinoma of the colon or breast. In three patients (33%), onset was during or immediately after completion of injection; in six patients (67%), onset was 30 minutes to 24 hours following dosing, suggesting a possible role of basophil and mast cell—derived nonhistamine mediators such as bradykinin. In seven patients (78%), facial flushing was accompanied by the following groups of transient reactions: rapid, thready pulse and hypotension;
Curran CF. Doxorubicin-Associated Facial Flushing. Arch Dermatol. 1992;128(10):1408. doi:10.1001/archderm.1992.01680200120029
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: